Canrenone as Add-on in Patients With Essential Hypertension
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 180 participants.
Also called NCT02687178
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 180 participants
- Sponsor
- Registry
-
NCT02687178
-
- Other papers using this trial's data
- Efficacy and safety of two dosages of canrenone as add-on therapy in hypertensive patients taking ace-inhibitors or angiotensin II receptor blockers and hydrochlorothiazide at maximum dosage in a randomized clinical trial: The ESCAPE-IT trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT02687178. Randomized; no masking; primary purpose treatment. Start 2010-10 (registry gives no type); primary completion 2015-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Canrenone as Add-on in Patients With Essential Hypertension
- Condition
- Essential Hypertension
- Intervention (Drug)
- Canrenone 50 vs canrenone 100 mg
- Lead sponsor
- University of Pavia
Record details
- Record id
cardio:ct-nct02687178- Content hash
96e61fdabad4c620d40bcdb79eb7673ad6244a9ce866e81f101cacc5f960e774